Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of a compound probiotic agent for preparing products for treating ulcerative colitis

A technology for ulcerative colitis and compound probiotics, which is used in the preparation of products for the treatment of ulcerative colitis and the field of compound probiotics, can solve the problem of low remission rate of ulcerative colitis, low selectivity of flora, and damage to the intestinal tract of patients. It can improve the immune system of the human body, improve the balance system, and promote the repair of various functions of the body.

Active Publication Date: 2021-07-09
BEIJING SCITOP BIO TECH CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The traditional method of treating ulcerative colitis is to take antibiotics orally, and antibiotics have low selectivity to the intestinal flora. When the pathogenic bacteria in the intestinal tract are killed, the probiotics in the intestinal tract will also be destroyed in large quantities. Kill, and then disrupt the balance of the intestinal flora of patients, resulting in a lower rate of remission of ulcerative colitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a compound probiotic agent for preparing products for treating ulcerative colitis
  • Application of a compound probiotic agent for preparing products for treating ulcerative colitis
  • Application of a compound probiotic agent for preparing products for treating ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] The preparation of embodiment 1 compound probiotic bacterial agent

[0080] The following takes Lactobacillus casei Zhang (Lactobacillus casei Zhang) as an example to illustrate the preparation of bacterial powder.

[0081] (1) Activation and cultivation of bacteria

[0082] The cryopreserved Lactobacillus casei Zhang (Lactobacillus casei Zhang) was inoculated in MRS liquid medium, cultured at 37°C for 20 hours, and then subcultured three times to obtain activated strains;

[0083] Among them, the MRS liquid medium was prepared according to the following proportions: 10g peptone, 5g beef extract, 4g yeast extract powder, 20g glucose, 2g dipotassium hydrogen phosphate, 5g sodium acetate, 2g trisodium citrate, 1mL Tween 80, 0.2g Add magnesium sulfate and 0.05g manganese sulfate to 1000mL distilled water, adjust the pH to 6.5, and sterilize at 121°C for 15min.

[0084] (2) High-density fermentation

[0085] The activated Lactobacillus casei Zhang was inoculated into a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The application provides the application of a composite probiotic agent for preparing products for treating ulcerative colitis. The compound probiotic bacterial agent contains 4 strains of probiotic lactic acid bacteria, namely Lactobacillus casei Zhang, Bifidobacterium animalis V9, Lactobacillus plantarum P-8 and Lactobacillus plantarum C2, these probiotics all have good acid resistance, artificial Gastrointestinal fluid tolerance and bile salt tolerance, and no drug-resistant plasmids, the 4 probiotic strains contained in it all have high safety. The compound probiotic bacterial agent also includes prebiotics, which can synergize with probiotics to ensure the beneficial function of probiotics. The compound probiotic agent provided by this application has a significant curative effect on ulcerative colitis, and can regulate the probiotic function of intestinal flora so as to make the intestinal flora healthy. The compound probiotic agent provided by this application is used as a treatment for ulcerative colitis Auxiliary drugs for colitis have the characteristics of simple treatment, high remission rate, and no side effects.

Description

technical field [0001] The application belongs to the field of biological preparations, and in particular relates to the use of a compound probiotic agent for preparing products for treating ulcerative colitis. Background technique [0002] Ulcerative colitis (Ulcerative colitis, UC) is a chronic non-specific intestinal inflammatory disease with unknown etiology and pathogenesis, and is a subtype of inflammatory bowel disease (Inflammatory bowel disease, IBD). The rate is increasing year by year globally. Ulcerative colitis mainly manifests as colonic mucosal lesions, mostly ulcers, and the lesions mostly occur in the rectum and sigmoid colon, and even involve the entire colon. Currently, UC is believed to be caused by multiple factors such as genetic factors, immune dysfunction, intestinal barrier dysfunction, and changes in intestinal microecology. [0003] The traditional method of treating ulcerative colitis is to take antibiotics orally, and antibiotics have low selec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A61K35/747A61P1/00A61P1/04A61K35/745A61K31/702A61K31/7004A61K31/606
CPCA61K31/606A61K31/7004A61K31/702A61K35/745A61K35/747A61P1/00A61P1/04A61K2300/00
Inventor 张凌宇杨慧娟张建军马杰宋继宏
Owner BEIJING SCITOP BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products